Children’s Hospital Los Angeles Awarded $6 Million from CIRM to Advance CAR T-Cell Therapies in Recurring Solid Tumors in Children
Retrieved on:
星期五, 三月 1, 2024
Biotechnology, Health Technology, Health, Oncology, Neoplasm, Division, Senior, Investigational New Drug, CHLA, Regenerative medicine, Doctor of Philosophy, Multimedia, CIRM, Transplant, FDA, CBDI, TGFB, Sarcoma, Cell, Radiation, Interim, Survival rate, Bone marrow, Hematology, Virus, Tumor microenvironment, USC, Patient, Clinical trial, Survival, Research, Medicine, Vaccine
Children’s Hospital Los Angeles has received a multi-year $6 million award from the California Institute for Regenerative Medicine (CIRM) to develop innovative stem cell approaches to treat children and adolescents with recurrent solid tumors.
Key Points:
- Children’s Hospital Los Angeles has received a multi-year $6 million award from the California Institute for Regenerative Medicine (CIRM) to develop innovative stem cell approaches to treat children and adolescents with recurrent solid tumors.
- (Photo: Business Wire)
When cancer reoccurs in children and young adults with solid tumors such as sarcomas and neuroblastomas, there are few good treatment options. - This is why Children’s Hospital Los Angeles researchers focus on finding novel therapies using the patient’s own immune cells to treat childhood cancers.
- In 2022, CIRM awarded $8 million to the Keck School of Medicine of USC and Children’s Hospital Los Angeles to establish a CIRM Alpha Clinic.